CELU News & Events

NexGel (NXGL) announced the consideration terms of its previously announced agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (CELU), a regenerative and cellular medicine company. Consideration for the portfolio will include a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on various annual net sales targets related to the portfolio. The transaction represents the most significant milestone in the Company's history and is expected to approximately triple NEXGEL's revenue base and expected to make the Company profitable immediately upon closing.

Celularity (CELU) reiterated that its strategic commercialization partnership with NEXGEL (NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement clarity around placental-derived biomaterials and build sales and market share. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions. "This strategic deal with NEXGEL allows Celularity to focus on a core strength-contract manufacturing-where we have demonstrated over many years our ability to scale and execute cost efficient biomaterial production at a pharmaceutical-like grade," said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer. "NEXGEL is the ideal partner to take these biomaterial products to the next level, with a disciplined, entrepreneurial approach and proven ability to drive value and market growth across industry verticals. Congratulations to the Celularity and NEXGEL teams as we look forward to closing the transaction in April."

NexGel (NXGL) announced the signing of a definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (CELU), a regenerative and cellular medicine company. The transaction represents the most significant milestone in the Company's history and is expected to approximately triple NEXGEL's revenue base and expected to make the Company profitable immediately upon closing.

Celularity announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions. The transaction is intended to monetize Celularity's commercial biomaterials portfolio while allowing the Company to concentrate resources on advancing its longevity-focused therapeutic pipeline. Under the terms of the agreements, Celularity granted an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs. The Company expects to receive upfront consideration at closing and may receive additional milestone-based payments totaling up to $35 million, representing non-dilutive capital. Celularity will also be eligible to receive royalties on future net sales of certain development-stage products upon commercialization.